Profile: Chimerix Inc (CMRX.OQ)
24 Mar 2017
Chimerix, Inc. (Chimerix), incorporated on April 7, 2000, is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available.
Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against over five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. It initiated the Phase III SUPPRESS trial of brincidofovir. The trial is designed to demonstrate the safety and efficacy of brincidofovir in the prevention of cytomegalovirus (CMV) infection through the first over 24 weeks following an allogeneic hematopoietic cell transplant (HCT) and will serve as the basis for Accelerated Approval for brincidofovir. The Company's AdVise trial is a Phase III study of brincidofovir for the treatment of adenovirus (AdV) infection in allogeneic HCT recipients and other immunocompromised patients. Chimerix, in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), is developing brincidofovir as a medical countermeasure to treat smallpox.
CMX157, is the Company's second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir is marketed under the brand name Viread, and in multiple fixed-dose combinations, which is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company, in collaboration with ContraVir Pharmaceuticals, is engaged in the development and commercialization of CMX157 for certain antiviral indications. The Company has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus (CMV). CMX669 has demonstrated potent in vitro activity against CMV and BK virus. It is evaluating CMX669 in preclinical testing.
The Company competes with Gilead Sciences, Inc., Hoffmann-La Roche Inc. and Clinigen Group plc.
2505 Meridian Pkwy Ste 100
DURHAM NC 27713-2288